Posts Tagged: healthcare technologies

$800,000 MaRS Innovation–Pfizer Translational Research Fund

KIRKLAND, Quebec and TORONTO, April 09, 2018 (GLOBE NEWSWIRE) -- Pfizer Canada is proud to announce an $800,000 contribution to MaRS Innovation to support the vision and mission of MaRS Innovation by providing funding for new ideas or technologies in the health sciences including; therapeutics, diagnostic and treatment tools, manufacturing technologies, and technologies that enable health sciences research. The MaRS Innovation – Pfizer Translational Research Fund will be managed by MaRS Innovation and projects in the area of cardiovascular disease, inflammation, immunology, ... Read more

Zucara Therapeutics Inc. Receives Support from NCR-IRAP

VANCOUVER and TORONTO, Canada — January 8, 2018 - Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, has received support of up to $350,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). In addition, The Centre for Drug Research and Development (CDRD) and MaRS Innovation have contributed follow on funding to the Company’s existing convertible note. Zucara recently defined its lead drug candidate, ZT-01, and ... Read more

Launch of Bright Angel Therapeutics

New York, NY and Toronto Canada, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Schrödinger, Inc., a privately-held company dedicated to revolutionizing drug discovery through advanced computational methods, and MaRS Innovation, a non-profit organization supporting the commercialization of research breakthroughs from Toronto’s leading academic institutions, today announced the launch of Bright Angel Therapeutics. The new Toronto-based company is focused on the development of novel therapeutics for treatment of drug-resistant and life-threatening fungal infections. Bright Angel’s first program is based on foundational research from ... Read more

Encycle Therapeutics announces discovery collaboration with Pfizer Inc.

TORONTO, November 1, 2017 – Encycle Therapeutics (“Encycle”), a Toronto-based drug discovery company built on a unique chemistry that enables the synthesis of a new type of constrained peptide called “nacellins,” today announced a research collaboration with Pfizer Inc. (“Pfizer”) (NYSE: PFE). Encycle and Pfizer will partner to optimize certain nacellins, which were previously identified by Pfizer during a screening of Encycle’s proprietary nacellin library, that act on an undisclosed therapeutic target. Nacellins are a type of peptide macrocycle that can often exhibit ... Read more

Ministry of Health and Long Term Care selects BresoTec for Sleep Apnea Test Project

Toronto, Canada, May 16, 2017 – BresoDx®, developed by BresoTec, has been selected by the Ministry of Health and Long-Term Care (MOHLTC) for use in a home-based sleep apnea demonstration project with sleep clinics across Ontario. For the first time in the province,patients and sleep physicians will have the option to diagnose sleep apnea in the home. Invented at the Toronto Rehabilitation Institute by Dr. Hisham Alshaer, BresoDx® is the world’s first cordless, single-user, home sleep test used to diagnose sleep apnea. BresoDx® aims ... Read more

Zucara Therapeutics Receives Cash Injection to Advance Novel Diabetes Drug Therapy to Prevent Hypoglycemia

VANCOUVER and TORONTO, Canada (November 3, 2016) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, announced it has received a $525,000 investment from Canadian partners: Accel-Rx Health Sciences Accelerator, The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI). This unique deal brings together three organizations mandated with enabling the growth of Canada’s health sciences sector. Each partner brings its respective strengths to the table: capital, ... Read more

Zucara Therapeutics inks license agreement with CDRD

This new license is an important step forward in bringing a new drug therapy closer to patients living with diabetes as it will enable us to access a promising lead drug candidate and position us to start clinical trials as early as 2018. Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, has signed a licensing agreement with The Centre for Drug Research and Development (CDRD) for access to a ... Read more

MaRS Innovation: Ahead of Innovation video launched

To coincide with our presence at the 2016 BIO International Convention (BIO) from June 6-9, 2016, MaRS Innovation launched a video explaining our role in Canada's innovation ecosystem: backing big thinkers with bold ideas and working with them to take those breakthroughs to market. This year, BIO takes place in San Francisco, California, the birthplace of biotech. MaRS Innovation will be present in the Ontario Pavilion (Booth #5944) in partnership with the Ontario Government and Life Sciences Ontario. Both the Honourable Navdeep Bains, Canada's ... Read more

Video: DashMD’s CEO and co-founder interviewed by Dx3 Canada

Amber Mac from Dx3 Canada interviewed Zack Fisch, CEO and co-founder of DashMD. In the video, Zack discusses DashMD's vision for a better healthcare system and what the company is doing in order to improve the discharge process for patients. About DashMD Dash MD seeks to improve the quality of healthcare by providing patients with the necessary tools, information, and resources that they need to successfully traverse their own personal and individualized road to recovery. Their Patient Engagement Platform will be downloadable to patients in ... Read more

Israel’s BioLineRx and Canada’s MaRS Innovation sign framework collaboration agreement

Agreement signed as part of Ontario's life sciences trade mission to Israel TEL AVIV and TORONTO (May 16, 2016) – BioLineRx Ltd. a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a framework collaboration agreement with MaRS Innovation,  the commercialization agent for 15 of Toronto's top academic institutions. Under the terms of the agreement, BioLineRx intends to review innovative projects and assets of start-up companies originating from MaRS Innovation's members to identify in-licensing, co-development or other ... Read more
Page 1 of 41234